Stock of the Day

89bio (ETNB)

$8.11

+$0.41 (+5.3%)

Market Cap: $1.18B

About 89bio

89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis; and for the treatment of severe hypertriglyceridemia.

The company was incorporated in 2018 and is headquartered in San Francisco, California.

Recent News

• 89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (globenewswire.com)
• 89bio to Participate in Upcoming Investor Conferences (globenewswire.com)